Wellcome Trust Sanger Institute Adopts DNASTAR Lasergene Software

DNASTAR has announced that the Wellcome Trust Sanger Institute entered into a multi-year software license agreement with DNASTAR for the use of Lasergene software as its primary sequence assembly and analysis software platform for researchers within its organization.

A spokesperson for the Wellcome Trust Sanger Institute said, “The Sanger Institute is one of the world’s leading genomics organizations and we have a real need for sequence analysis software that performs. Our researchers need access to a common set of tools that help them to share data: that is part of our Institute ethos. The solution for our analysis must be flexible and able to respond to changing demands.”

Tom Schwei, Vice President and General Manager of DNASTAR, stated, “We are delighted to have entered into this agreement with the Wellcome Trust Sanger Institute, a recognized global leader in genomic research. This site license will support scientists and staff at the Sanger Institute in all of their scientific research endeavors for many years to come. As we continue to develop our software, all scientists within the Institute will benefit by having immediate access to the most recent innovations in our products. We appreciate the trust placed in our software, support, and company by the Sanger Institute and we look forward to continuing to meet their sequence assembly and analysis software needs in the future.”

Financial terms of the arrangement were not disclosed.

Note: The Wellcome Trust Sanger Institute does not endorse commercial products.